Why choose KHINDIVI?

Dosing made easier

KHINDIVI helps make dosing simple and accurate. When taken as prescribed, it gives each child the right amount they need. It’s a helpful treatment for children 5 years and older with adrenal insufficiency

Improved tolerance

KHINDIVI is a liquid, which can help children who have trouble swallowing pills or don’t like the taste or feel of tablets

Convenience for families

KHINDIVI comes as a ready-to-use liquid. There’s no need to mix, shake, or keep it in the fridge—just give as prescribed

Approved for gastric tubes

KHINDIVI can be given through a g-tube. After giving the medicine, flush the tube with water to make sure your child gets the full dose

Caregiver resources

Get access to downloadable resources, online tools, and support groups to help you through your child’s treatment journey

Expert support

Get additional tools and tips and full support through our Eton Cares Program

Too much or too little hydrocortisone can cause serious health problems and may lead to a medical emergency

A tablet icon with an arrow pointing up for overdosing.
Overdosing

Too much hydrocortisone can lead to2-5*:

  • Cardiovascular disease
  • Cushing’s syndrome
  • Osteoporosis
  • Growth issues
  • High blood pressure
  • Abnormal weight gain
A tablet icon with an arrow pointing down for underdosing.
Underdosing

Not enough hydrocortisone can lead to2-5*:

  • Adrenal crisis
  • Disruption of bodily functions
  • Male hormone exposure and rapid growth
  • Low blood pressure
  • Salt cravings
  • Weight loss
  • Generally feeling unwell

*No representation is made regarding the effect of KHINDIVI on these conditions.

Designed to help get dosing right every time

KHINDIVI is given by mouth using a syringe from Anovo® Specialty Pharmacy.
The syringe helps you measure each dose accurately as prescribed.

A syringe icon for accurate liquid dosing.

The liquid form of KHINDIVI makes it easy to adjust the dose to help your child get the treatment that’s right for them

A tablet icon with an X for no more cutting or splitting pills.

Easy to store without the need to refrigerate, mix, or shake

A snowflake icond with an X for no need to refrigerate KHINDIVI.

No mixing at the pharmacy or cutting, splitting, or crushing tablets

A raspberry icon for the berry flavor of KHINDIVI.

A berry flavor that may help encourage children to take their medicine

Have questions about KHINDIVI?

USE AND IMPORTANT SAFETY INFORMATION

USE

KHINDIVI is a prescription medicine used in children 5 years of age and older as replacement therapy when the adrenal gland is not making enough cortisol.

Limitation of Use: KHINDIVI is not approved for increased dosing during periods of stress or acute events. Use a different hydrocortisone-containing drug product for stress dosing.

IMPORTANT SAFETY INFORMATION

Always give KHINDIVI exactly as your doctor has directed.

Do not take KHINDIVI if you are allergic to hydrocortisone or any of its other ingredients.

Adrenal Crisis: Giving too low a dose or stopping medication can cause low levels of cortisol, which can result in serious illness or death. Treatment with intravenous hydrocortisone should be started immediately. When switching from another type of hydrocortisone to KHINDIVI, watch your child closely for any changes. During periods of stress such as infections or after surgery, your doctor should switch to another oral hydrocortisone product and increase the dose.

Systemic Adverse Reactions Due to Inactive Ingredients
Hyperosmolarity: KHINDIVI is not approved in children less than 5 years of age. The inactive ingredients in KHINDIVI can cause dangerous fluid imbalances.

Metabolic Acidosis and Other Adverse Reactions: Some ingredients in KHINDIVI may cause a build-up of acid in the body, low blood sugar, or injuries to the liver, kidneys, or brain, that may increase the risk of adrenal crisis.

Laxative Effects Due to Inactive Ingredients: Some ingredients in KHINDIVI may cause stomach upset resulting in vomiting and/or diarrhea and could increase the risk of adrenal crises in patients.

Immunosuppression and Increased Risk of Infection With Use of a Dosage Greater Than Replacement: Use of a greater than replacement dosage can suppress the immune system and increase the risks of new infections. Contact your health care provider if any infections develop.

Growth Retardation: The long-term use of corticosteroids in high doses may cause growth retardation in children.

Decrease in Bone Density: Corticosteroids can affect your child’s bone growth and strength.

Cushing’s Syndrome Due to High Doses of Corticosteroids: Treatment with high doses of corticosteroids can cause Cushing’s Syndrome. Treatment should be limited to the smallest dose required, and your child’s growth and development monitored appropriately.

Psychiatric Changes: Corticosteroids can change your child’s behavior or mood. Tell your doctor if your child has periods of extreme happiness, extreme sadness, hallucinations, or depression.

Changes in Vision: Tell your doctor if your child has blurred vision or other vision problems during treatment with KHINDIVI.

Gastrointestinal Adverse Reactions: Tell the doctor if your child has stomach pain, upset stomach, black, tarry stools, or vomiting of blood. These could be signs of ulcers or tears in the stomach or intestines. Taking anti-inflammatory nonsteroidal drugs, like ibuprofen, naproxen, or aspirin, can increase the risk of ulcers or tears.

The most common side effects of KHINDIVI include retaining fluids, changes in glucose tolerance, high blood pressure, behavioral and mood changes, greater appetite, and weight gain.

Vaccination: Administration of live vaccines may be acceptable in KHINDIVI-treated pediatric patients with adrenocortical insufficiency who receive replacement corticosteroids.

Please visit KHINDIVI.com/patient for more information.

You are encouraged to report negative side effects of prescription drugs by contacting Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for more information.

USE AND IMPORTANT SAFETY INFORMATION

USE

KHINDIVI is a prescription medicine used in children 5 years of age and older as replacement therapy when the adrenal gland is not making enough cortisol.

Limitation of Use: KHINDIVI is not approved for increased dosing during periods of stress or acute events. Use a different hydrocortisone-containing drug product for stress dosing.

IMPORTANT SAFETY INFORMATION

Always give KHINDIVI exactly as your doctor has directed.

Do not take KHINDIVI if you are allergic to hydrocortisone or any of its other ingredients.

Adrenal Crisis: Giving too low a dose or stopping medication can cause low levels of cortisol, which can result in serious illness or death. Treatment with intravenous hydrocortisone should be started immediately. When switching from another type of hydrocortisone to KHINDIVI, watch your child closely for any changes. During periods of stress such as infections or after surgery, your doctor should switch to another oral hydrocortisone product and increase the dose.

Systemic Adverse Reactions Due to Inactive Ingredients
Hyperosmolarity: KHINDIVI is not approved in children less than 5 years of age. The inactive ingredients in KHINDIVI can cause dangerous fluid imbalances.

Metabolic Acidosis and Other Adverse Reactions: Some ingredients in KHINDIVI may cause a build-up of acid in the body, low blood sugar, or injuries to the liver, kidneys, or brain, that may increase the risk of adrenal crisis.

Laxative Effects Due to Inactive Ingredients: Some ingredients in KHINDIVI may cause stomach upset resulting in vomiting and/or diarrhea and could increase the risk of adrenal crises in patients.

Immunosuppression and Increased Risk of Infection With Use of a Dosage Greater Than Replacement: Use of a greater than replacement dosage can suppress the immune system and increase the risks of new infections. Contact your health care provider if any infections develop.

Growth Retardation: The long-term use of corticosteroids in high doses may cause growth retardation in children.

Decrease in Bone Density: Corticosteroids can affect your child’s bone growth and strength.

Cushing’s Syndrome Due to High Doses of Corticosteroids: Treatment with high doses of corticosteroids can cause Cushing’s Syndrome. Treatment should be limited to the smallest dose required, and your child’s growth and development monitored appropriately.

Psychiatric Changes: Corticosteroids can change your child’s behavior or mood. Tell your doctor if your child has periods of extreme happiness, extreme sadness, hallucinations, or depression.

Changes in Vision: Tell your doctor if your child has blurred vision or other vision problems during treatment with KHINDIVI.

Gastrointestinal Adverse Reactions: Tell the doctor if your child has stomach pain, upset stomach, black, tarry stools, or vomiting of blood. These could be signs of ulcers or tears in the stomach or intestines. Taking anti-inflammatory nonsteroidal drugs, like ibuprofen, naproxen, or aspirin, can increase the risk of ulcers or tears.

The most common side effects of KHINDIVI include retaining fluids, changes in glucose tolerance, high blood pressure, behavioral and mood changes, greater appetite, and weight gain.

Vaccination: Administration of live vaccines may be acceptable in KHINDIVI-treated pediatric patients with adrenocortical insufficiency who receive replacement corticosteroids.

Please visit KHINDIVI.com/patient for more information.

You are encouraged to report negative side effects of prescription drugs by contacting Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for more information.

References: 1. KHINDIVI. Package insert. Eton Pharmaceuticals, Inc; 2025. 2. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. doi:10.1210/jc.2015-1710 3. Han TS, Conway GS, Willis DS, et al. Relationship between final height and health outcomes in adults with congenital adrenal hyperplasia: United Kingdom congenital adrenal hyperplasia adult study executive (CaHASE). J Clin Endocrinol Metab. 2014;99:E1547-E1555. doi:10.1210/jc.2014-1486 4. Oprea A, Bonnet NCG, Pollé O, Lysy PA. Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency. Ther Adv Endocrinol Metab. 2019;10:2042018818821294. doi:10.1177/2042018818821294 5. Debono M, Newell Price J, Ross RJ. Novel strategies for hydrocortisone replacement. Best Pract Res Clin Endocrinol Metab. 2009;23(2):221-232. doi:10.1016/j.beem.2008.09.010